**Table 1.** Select outcomes of ASCT for relapsed or refractory FL

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Number of Patients | | R included in salvage CT | PFS | OS | Ref |
| Schouten et al, 2000 | 65 | | 0 | 55-58% at 2 year | 71-77% at 4 year | 24 |
| Rohatiner et al, 2007 | 121 | | 0 | 55% at 5 year | 71% at 5 years | 44 |
| Sebban, et al, 2008 | 98 | | 33% | 51% at 5 year | 70% at 5 year | 45 |
| Vose, et al, 2008 | 248 | | Few (not reported) | 44% at 5 year | 63% at 5 year | 46 |
| Tarella et al, 2008 | 61+ | | 100% | 57 at 5 year | 75% at 5 year | 25 |
| Le Gouill et al, 2011 | 112\* | | 100% | 52 at 3 year | 92% at 3 year | 43 |
| Le Gouill et al, 2011 | 53\* | | 0 | 40 at 3 year | 63% at 3 year | 43} |
| Evens et al, 2013 | 135 | | 100% | 57% at 3 year | 87% at 3 year | 83 |
| Pettengell et al, 2013 | 280 | | 0 | 48-42% at 10 years | 66.1-74.5% at 10 year | 50 |
| Klyuchnikov et al#, 2015 | 250 | | 100% | 41% at 5 year | 74% at 5 year | 41 |
| Klyuchnikov et al$, 2015 | 136 | | 100% | 36% at 5 year | 59 at 5 year | 42 |
|  |  |  | |  |  |  |

+ considered only R-HDS arm

\*Considering the trial end point, bot arm (with and without rituximab) are listed

#Only Grade 2 FL were included in this study

$Only Grade 3 FL were included in this study